Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Kansas Adstiladrin Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross and Blue Shield of KansasPolicy N/A

    Adstiladrin

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, dosing, renewal, and coding requirements for intravesical Adstiladrin (nadofaragene firadenovec-vncg) in adult members with qualifying high-risk, BCG-unresponsive non-muscle-invasive bladder cancer. Coverage is subject to the member contract, applicable mandates, and the clinical criteria in this policy.

    Policy Summary
    PayerBlue Cross and Blue Shield of Kansas
    PolicyAdstiladrin
    Policy CodePolicy N/A
    Change TypeNew policy publication
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of high-risk disease unresponsive to adequate BCG therapy before initiating Adstiladrin.
    SourceLink
    POLICY UPDATE CHANGES

    A new Adstiladrin medical policy was added to the BCBSKS website.

    18+Minimum member age
    1 dose/3 monthsDosing limit
    6 monthsAuthorization validity
    BCG-unresponsive NMIBCDisease setting

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J9029
    HCPCS code
    4Vials per carton

    Coverage Criteria

    Universal initial approval criteria

    Initial approval requires all universal criteria.

    Universal criteria

    • Eligibility and administration

      • Member is at least 18 years of age.Age ≥18 years
      • Member does not have hypersensitivity to interferon alfa.
      • Member is not immunosuppressed or immunodeficient.
      • Therapy will be administered by intravesical instillation only.
      • Adstiladrin will be used as a single agent.

    BCG-unresponsive NMIBC initial criteria

    The member must meet all disease-specific criteria, including one qualifying tumor presentation.

    BCG-unresponsive bladder cancer eligibility

    • Member has non-muscle-invasive bladder cancer.High-risk BCG-unresponsive NMIBC
    • Qualifying tumor presentation

      • Member has carcinoma in situ, with or without papillary tumors.
      • Member has high-grade papillary Ta/T1 tumors without carcinoma in situ.
    • Member has high-risk disease unresponsive to Bacillus Calmette-Guerin (BCG).

      BCG-unresponsive disease includes persistent disease following adequate BCG therapy, recurrence after an initial tumor-free state following adequate BCG therapy, or T1 disease following a single induction course of BCG.

    Continuation and renewal criteria

    Renewal requires continued eligibility, treatment response, and absence of unacceptable toxicity.

    Renewal criteria

    • Member continues to meet the applicable universal and indication-specific criteria.
    • Disease response is demonstrated by stabilization of disease or a decrease in tumor size or tumor spread.Disease stable or improved
    • Member has no unacceptable toxicity from treatment, including disseminated adenovirus infection.
    • Renewal-stage response

      • For the first renewal, member has a complete response, defined as a negative cystoscopy with TURBT/biopsies as applicable and negative urine cytology.First renewal: complete response

    Coverage excludes extra-vesical urothelial carcinoma involving the urethra, ureter, or renal pelvis; muscle-invasive disease staged T2-T4; and metastatic urothelial carcinoma. The member must have qualifying high-risk, BCG-unresponsive non-muscle-invasive bladder cancer after TURBT removes all resectable Ta and T1 disease.

    Adstiladrin is covered only when administered by intravesical instillation via a urinary catheter. Intravenous, topical, and oral administration are excluded and do not meet the policy’s administration requirement.

    Coding and Billing Requirements

    Covered HCPCS CodesHCPCSCovered
    J9029Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose; 1 billable unit = 1 dose
    Covered NDC CodesNDCCovered
    555661050-xxAdstiladrin suspension, with nominal concentration of 3 × 10^11 viral particles (vp)/mL in a carton of four frozen single-dose vials with an extractable volume of 20 mL/vial
    Dosing frequency
    Billable amount1 billable unit (1 dose)
    FrequencyEvery 3 months
    Treatment intervalOne dose per 3-month period
    Adequate BCG induction
    Minimum induction exposureAt least 5 induction doses
    Full induction course6 induction doses
    Qualifying threshold≥5 of 6 induction doses

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Six-Month Prior Authorization

    Prior authorization is required before treatment. Initial authorization is valid for 6 months (180 days), and renewal authorization may be requested every 6 months thereafter.

    • Initial authorization: 6 months (180 days)
    • Renewal authorization: every 6 months (180 days)
    Documentation Required

    Prior Adequate BCG Therapy Required

    Document that the member has high-risk NMIBC that is unresponsive to adequate BCG therapy. Adequate BCG requires at least 5 of 6 induction doses plus either at least 2 maintenance doses or at least 2 doses of a second induction course.

    • BCG-unresponsive disease may include persistent disease after adequate BCG, recurrence after an initially tumor-free state following adequate BCG, or T1 disease after a single induction course
    • Adequate BCG: ≥5 of 6 induction doses plus either ≥2 maintenance doses or ≥2 doses of a second induction course

    Therapy Overview

    Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy administered by intravesical instillation for adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer. The recommended dose is 75 mL at 3 × 1011 viral particles per mL once every 3 months; premedication with an anticholinergic is recommended before each instillation.

    Clinical Definitions

    BCG-unresponsive disease
    Persistent diseaseDisease persists following adequate BCG therapy
    RecurrenceDisease recurs after an initial tumor-free state following adequate BCG therapy
    T1 diseaseT1 disease follows a single induction course of BCG
    Adequate BCG therapy
    Induction requirementAt least 5 of 6 induction BCG doses
    Maintenance requirementAt least 2 maintenance doses
    Alternative second induction requirementAt least 2 doses of a second induction course

    Initial Adstiladrin Approval

    Initial Adstiladrin approval

    Initial Adstiladrin therapy is authorized when all universal and bladder-cancer-specific criteria are satisfied.

    Initial Adstiladrin therapy

    • Member is at least 18 years old.Age ≥18 years
    • Member does not have hypersensitivity to interferon alfa.
    • Member is not immunosuppressed or immunodeficient.
    • Therapy will be administered by intravesical instillation only and used as a single agent.
    • Qualifying bladder cancer

    Adstiladrin Renewal

    Adstiladrin renewal

    Renewal authorization may be granted every 6 months when all continuation criteria are met.

    Adstiladrin continuation therapy

    • Member continues to meet the applicable universal and indication-specific criteria.
    • Disease has stabilized or decreased in tumor size or tumor spread.Disease stable or improved
    • Member has no unacceptable toxicity from treatment, including disseminated adenovirus infection.
    • Applicable renewal-stage response

    Prerequisite Therapy

    StepRequirementDetails
    1Document high-risk disease unresponsive to adequate Bacillus Calmette-Guerin (BCG) therapy before Adstiladrin initiation.Adequate BCG therapy requires at least 5 of 6 induction doses plus either at least 2 doses of maintenance therapy or at least 2 doses of a second induction therapy.

    Product Quantity and Dose

    Adstiladrin quantity limits
    Dose volume75 mL
    Concentration3 x 10^11 viral particles per mL
    Quantity limit1 billable unit (1 dose) every 3 months

    Administration Setting

    Note

    Administer intravesically through a urinary catheter

    Adstiladrin must be administered by intravesical instillation through a urinary catheter only.

    Policy Summary
    PayerBlue Cross and Blue Shield of Kansas
    PolicyAdstiladrin
    Policy CodePolicy N/A
    Change TypeNew policy publication
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of high-risk disease unresponsive to adequate BCG therapy before initiating Adstiladrin.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing RequirementsAuthorization, Documentation, and Denial RisksTherapy OverviewClinical DefinitionsInitial Adstiladrin ApprovalAdstiladrin RenewalPrerequisite TherapyProduct Quantity and DoseAdministration Setting
  1. Member has undergone transurethral resection of bladder tumor (TURBT) to remove all resectable Ta and T1 disease.
  2. Member does not have extra-vesical urothelial carcinoma involving the urethra, ureter, or renal pelvis; muscle-invasive urothelial carcinoma staged T2-T4; or metastatic urothelial carcinoma.
  3. For subsequent renewals, member has not experienced a high-grade or carcinoma-in-situ recurrence.Subsequent renewals: no high-grade or CIS recurrence
  4. Adequate BCG maintenance or second induction
    Maintenance optionAt least 2 doses of maintenance therapy
    Second induction optionAt least 2 doses of a second induction therapy
    Required contextEither option follows at least 5 of 6 induction BCG doses
    Documentation Required

    Required Clinical Documentation

    Submit supporting clinical documentation with every authorization request so medical necessity can be evaluated. Records should support the diagnosis, applicable treatment history, clinical markers, and other relevant medical-necessity criteria.

    • Medical records and chart notes
    • Laboratory results and confirmatory diagnostics
    • Documentation of diagnosis, step therapy, and applicable genetic or mutational testing
    • Upload through the prior authorization portal or submit by fax
    Documentation Required

    Initial Disease Eligibility Records

    Initial records must establish eligible NMIBC and the qualifying disease presentation. Document CIS with or without papillary tumors, or high-grade papillary Ta/T1 tumors without CIS, along with high-risk BCG-unresponsive disease and TURBT removing all resectable Ta and T1 disease.

    • Diagnosis of non-muscle-invasive bladder cancer (NMIBC)
    • CIS with or without papillary tumors, or high-grade papillary Ta/T1 tumors without CIS
    • High-risk disease unresponsive to BCG
    • TURBT completed to remove all resectable Ta and T1 disease
    • No extra-vesical, muscle-invasive T2-T4, or metastatic urothelial carcinoma
    Documentation Required

    Renewal Response Documentation

    For renewal, document that the member continues to meet applicable universal and indication-specific criteria, has disease stabilization or reduction, and has no unacceptable toxicity. Renewal records must also show the required response for the renewal stage.

    • First renewal: complete response with negative cystoscopy, with TURBT or biopsies as applicable, and negative urine cytology
    • Subsequent renewals: no high-grade or CIS recurrence
    • Document disease stabilization or decreased tumor size or spread
    • Document absence of unacceptable toxicity, such as disseminated adenovirus infection
    Denial Risk

    Failure to Meet Criteria or Submit Records

    Requests may be denied when universal criteria, indication-specific medical necessity, or required supporting records are not established. Submit complete documentation and confirm all treatment restrictions before requesting authorization.

    • Member must be at least 18 years old
    • No hypersensitivity to interferon alfa
    • Member is not immunosuppressed or immunodeficient
    • Use is limited to intravesical instillation as a single agent
    • Missing medical records may prevent establishment of medical necessity
    Denial Risk

    Ineligible Bladder Cancer Stage or Spread

    Adstiladrin is not eligible under this policy for extra-vesical, muscle-invasive, or metastatic urothelial carcinoma.

    • Extra-vesical disease involving the urethra, ureter, or renal pelvis
    • Muscle-invasive disease staged T2-T4
    • Metastatic urothelial carcinoma
    Denial Risk

    Failure of Renewal Criteria

    Renewal may be denied when the member no longer meets eligibility criteria, the required response is not documented, unacceptable toxicity occurs, or the applicable first or subsequent renewal response requirement is not met.

    • No continued fulfillment of universal or indication-specific criteria
    • No disease stabilization or reduction in tumor size or spread
    • Unacceptable toxicity from treatment
    • No complete response at first renewal
    • High-grade or CIS recurrence at a subsequent renewal
    Billing Rule

    Improper Administration or Product Handling

    Administer Adstiladrin by intravesical instillation only; do not administer it intravenously, topically, or orally. Follow biosafety and handling requirements, and do not use product with visible particles or discoloration.

    • Recommended dose: 75 mL at 3 × 1011 viral particles/mL by intravesical instillation once every 3 months via urinary catheter
    • Use universal biosafety precautions; immunosuppressed or immunodeficient individuals must not prepare, administer, or contact the product
    • Thaw all four vials and bring them to 20°C to 25°C (68°F to 77°F); do not expose them to temperatures above 25°C (77°F)
    • Visually inspect all four vials; do not use if visible particles or discoloration are observed
    • Mix gently; do not shake
    Complete response
    CystoscopyNegative cystoscopy
    TURBT or biopsiesTURBT or biopsies as applicable
    Urine cytologyNegative urine cytology
    • Member has non-muscle-invasive bladder cancer.
    • Qualifying tumor presentation

      • Carcinoma in situ, with or without papillary tumors.
      • High-grade papillary Ta/T1 tumors without carcinoma in situ.
    • Member has high-risk disease unresponsive to adequate BCG therapy.

      Adequate BCG therapy requires at least 5 of 6 induction doses plus either at least 2 maintenance doses or at least 2 doses of a second induction course.

    • Member has undergone TURBT to remove all resectable Ta and T1 disease.
    • Member does not have extra-vesical, muscle-invasive T2-T4, or metastatic urothelial carcinoma.
    For the first renewal, member has a complete response, defined as a negative cystoscopy with TURBT/biopsies as applicable and negative urine cytology.
    First renewal: complete response
  5. For subsequent renewals, member has not experienced a high-grade or carcinoma-in-situ recurrence.Subsequent renewals: no high-grade or CIS recurrence